This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Mike Caswell

The B.C. Securities Commission has halted trading in Noveris Health Sciences Inc., a Canadian Securities Exchange listing that went to $2.20 from 42 cents in five days as a tout service inaccurately described the company as "FDA-registered." The BCSC says that there are "unexplained and unusual fluctuations" in the company's trading. As a result, it has halted the stock until April 16, 2026.

The halt is contained in a brief order that the BCSC issued on Thursday, March 26. The sole target of the order is Noveris, which trades on the CSE as well as the OTC Markets and the Frankfurt stock exchange (or, more formally, the Borse Frankfurt). The BCSC notes that the stock increased by 423 per cent over a brief period -- between March 13 and March 19, 2026, with its average daily volume hitting 194,731 shares.

The brief order provides few details of the reasons for the halt, citing "publicly available promotional articles that contain untrue and misleading statements about Noveris' business and prospects." While the BCSC has little to say, the source of those materials is at least partly an article published under the name John Michaels, which referred to Noveris as having registration with the FDA. The reference presumably refers to the U.S. Food and Drug Administration, with which all commercial drug producers must be registered.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS